It is no secret among doctors that many established medical and surgical treatments have been inadequately evaluated. Even when they have been studied in population samples there is always an element of empiricism when they are tried in a particular case. It is often appropriate to share some of this uncertainty with our patients but hardly anyone would advocate providing an elaborate account of all the uncertainties and imponderables associated with everyday treatments. Most patients do not wish to receive such detailed information and generally trust the judgement of the profession.
The introduction of a new treatment is quite another matter. Most patients expect and have a right to know whether the treatment that they are being offered is novel; and the public is not happy to let doctors experiment with new treatments without a proper level of information and appropriate safeguards. The Applying to the local research ethics committee should not be seen as an obstacle or a threat to research. Most ethics committees are strongly in favour of potentially useful and well conducted research and seek only to ensure that the interests of participants are protected by a proper consideration of the risks and by the provision of adequate, intelligible, and honest information to patients. If these conditions are met and if the need to apply to the ethics committee is considered sufficiently early in the development of the project, applying to the ethics committee is not a barrier to progress.
Multicentre projects are more of a problem. The lot of a group of innovative clinicians attempting a multicentre study requiring approval from numerous ethics committees is not a happy one. Even if all committees were straightforward in their approach and were efficient, a considerable amount of work would be involved. If some of the committees are excessively fussy and long-winded it can be a nightmare. Fortunately, there are now advanced proposals for a degree of centralisation and streamlining of the process of ethical approval for multicentre projects and so life should soon become easier.
In the treatment of congenital heart disease, whether it be by drugs, open surgery, or a transvascular procedure, the need for ethics committee approval is as clear as anywhere else in medicine. Judging whether the proposed treatment is sufficiently new to require submission to an ethics committee will remain a problem, but there can be no complaint if clinicians err on the side of applying to the ethics committee when in doubt. Since paediatric cardiology is, happily, a clinical specialty in which improvements in outcome through research and development continue to occur at a rapid pace, ethics committees can anticipate a continuing challenge to their judgement for many years to come.
One point worthy of emphasis is that there is no difference between a novel surgical procedure and a novel drug treatment as far as the need to apply to the ethics committee is concerned. In either case, if significant new ground is being broken and the results are potentially publishable there is a need for informed consent from the patient and this should be underwritten by ethics committee approval. Surgeons may long have viewed themselves as creative artists working free of constraint, and clearly they must, like all practitioners, be allowed a considerable degree of clinical freedom. It is difficult to construct a logical argument that applies different standards to surgical and medical innovative procedures, however.
The principles of obtaining informed consent for the evaluation of novel treatments involving children are quite clear. Firstly, when the child is judged too young or too sick to be personally involved in giving consent, informed consent from the parents or legal guardians is acceptable. Secondly, when the child is judged to be old enough and well enough to contribute to the decision making process, albeit in a limited way, an attempt should be made to engage the child's opinion appropriately. Thirdly, every effort should be made to minimise the adverse effects of procedures undertaken solely for research purposes. Though an adult may be approached to submit to serial venepuncture for research purposes a child should generally not be expected to behave so altruistically. Everything possible should be done to minimise pain and discomfort.
To summarise, those contemplating the introduction of a novel treatment of any kind in paediatric cardiology should always consider whether or not ethics committee approval is required: when in doubt they should seek approval. They should ensure that their application to the ethics committee can be clearly understood by colleagues in other specialties and by lay people. In particular, they should ensure that the written information sheet for parents/patients provides a clear account of what is proposed. It must be honest about any important risks and written in plain English at a level that can be understood by a 12 year old. 
